Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
Previous Symbol
CUSIPN/A
Phone650-870-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio13.66
Quick Ratio13.66
Price-To-Earnings
Trailing P/E Ratio-5.10
Forward P/E Ratio-2.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.95 million
Price / Sales6.29
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.24 per share
Price / Book1.01
Profitability
EPS (Most Recent Fiscal Year)($0.84)
Net Income$-27,820,000.00
Net Margins-90.65%
Return on Equity-31.73%
Return on Assets-27.21%
Miscellaneous
Employees73
Outstanding Shares38,130,000
Market Cap$175 million
OptionableOptionable
Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions
What is Calithera Biosciences' stock symbol?
Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."
How were Calithera Biosciences' earnings last quarter?
Calithera Biosciences Inc (NASDAQ:CALA) posted its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.12. Calithera Biosciences had a negative return on equity of 31.73% and a negative net margin of 90.65%. View Calithera Biosciences' Earnings History.
When is Calithera Biosciences' next earnings date?
What price target have analysts set for CALA?
2 brokers have issued 1-year price objectives for Calithera Biosciences' stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 227.1% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.
What is the consensus analysts' recommendation for Calithera Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.
Has Calithera Biosciences been receiving favorable news coverage?
Press coverage about CALA stock has been trending somewhat positive recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Calithera Biosciences earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the near term.
Who are some of Calithera Biosciences' key competitors?
Some companies that are related to Calithera Biosciences include ProQR Therapeutics (PRQR), Principia Biopharma (PRNB), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Rocket Pharmaceuticals (RCKT), Eagle Pharmaceuticals (EGRX), Omeros (OMER), Viking Therapeutics (VKTX), Inflarx (IFRX), ANI Pharmaceuticals (ANIP), Vectura Group (VEGPF), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Eidos Therapeutics (EIDX) and Karyopharm Therapeutics (KPTI).
Who are Calithera Biosciences' key executives?
Calithera Biosciences' management team includes the folowing people:
- Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 64)
- Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 44)
- Dr. Keith Orford, Sr. VP of Clinical Devel. (Age 46)
- Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 44)
- Ms. Jennifer McNealey, VP of Investor Relations & Strategy
Who are Calithera Biosciences' major shareholders?
Calithera Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.39%), Vanguard Group Inc (3.39%), Dimensional Fund Advisors LP (2.59%), Man Group plc (1.96%), JPMorgan Chase & Co. (0.63%) and JPMorgan Chase & Co. (0.59%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.
Which major investors are selling Calithera Biosciences stock?
CALA stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Renaissance Technologies LLC, Man Group plc, Bridgeway Capital Management Inc., Prudential Financial Inc., AQR Capital Management LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Calithera Biosciences.
Which major investors are buying Calithera Biosciences stock?
CALA stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, JPMorgan Chase & Co., JPMorgan Chase & Co., Vanguard Group Inc, Vanguard Group Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Calithera Biosciences.
How do I buy shares of Calithera Biosciences?
Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Calithera Biosciences' stock price today?
One share of CALA stock can currently be purchased for approximately $4.28.
How big of a company is Calithera Biosciences?
Calithera Biosciences has a market capitalization of $175 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.
What is Calithera Biosciences' official website?
How can I contact Calithera Biosciences?
Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]
MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
